logo-loader
viewEquillium

Equillium 'excited' about data from three different Phase IB clinical studies in second half of 2020

Equillium Inc (NASDAQ:EQ) CEO Bruce Steel sat down with Proactive’s Christine Corrado at BIO CEO in New York. The San Diego-based biotechnology company is developing products for autoimmune and inflammatory disorders.

Quick facts: Equillium

Price: 2.62 USD

NASDAQ:EQ
Market: NASDAQ
Market Cap: $45.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 22 hours ago

2 min read